Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| In addition, a favorable injection site reaction profile has been seen with the new drug product in nonclinical studies |
| Each of our programs has a first or best in class profile, which has highly differentiating features, and each of these are substantial market opportunities |
| As we've discussed before, GeneTAC small molecules have several potential advantages over any other genomic medicine modalities |
| So we feel that the exciting results we've seen with the plasma PK do also set us up well for good tissue distribution |
| Success in any one of these programs has the potential to generate enormous value for patients and shareholders |
| This would be a best-in-class profile |
| Having seen these exciting profiles, we are encouraged at the preliminary non-GLP tolerability of these molecules in both rodents and non-human primates |
| We are very encouraged to see this in vivo confirmation of the activity seen in cells derived from patients |
| In summary, we have a promising new platform for genomic medicine that is meaningfully differentiated from other genomic medicine modalities |
| We have robust assays that we've already used in prior clinical studies for measurement of frataxin RNA, and we continue to make improvements on our ability to reliably measure frataxin protein and possible changes and frataxin protein |
| Skyclarys is now approved for the treatment of FA and its update confirms that this is a large market opportunity |
| And in fact, in one arm of the study, we've included daily injections over four weeks, which gives us further confidence that the injection site tolerability issues appear resolved |
| The new drug product also shows that the tissue levels as measured by muscle biopsy in non-human primates is in line with plasma exposures, providing comfort that the extended profile seen in plasma will provide the desired extended profile in tissues |
| And that's what's so exciting about Design, is we have an opportunity to provide a restorative therapy of natural frataxin from the patient's own genes and to do it with a small molecule |
| Design's genomic medicine platform has the potential to surpass competing modalities like gene editing and gene therapy for the treatment of these diseases |
| In addition, we have a five-year operating runway, which enables us to generate clinical proof of concept on up to four programs |
| Repeat dose studies done in non GLP assessments have also been encouraging and the program will be proceeding to GLP studies, which are planned to be completed by the end of this year to support patient dosing in 2025 |
| Design’s approach is more cost effective, making an investment decision for a longer horizon potentially quite attractive |
| This restores frataxin levels and therefore cellular health |
| Each of the programs we are pursuing in these areas have the potential to be first in class or best in class |
| And success in any one of these would create significant value for investors |
| What makes this company unique and compelling is that we have discovered a new class of small molecules that are designed to dial up or dial down the expression of an individual gene in the genome |
| We are dedicated to moving these molecules forward and welcome you to participate in this journey and help us get to success |
| This is particularly encouraging because regardless of the genotype, it is known that the repeats undergo somatic expansion of various lengths in different neurons over time, and this data suggests that the compound would have an even more profound impact on those cells, which have undergone a longer somatic expansion of their CAG repeats |
| I'm excited to present Design Therapeutics’ First Significant Update for 2024 |
| It would be highly desirable and a best-in-class profile to have a selective inhibitor of mutant DMPK for the treatment of myotonic dystrophy that would distribute broadly in all affected tissues and cell types |
| As we showed in the beginning, the new drug product, DT-216P2 has a much more sustained exposure profile as seen in the single dose ID PK curve from non-human primates |
| We have four drug programs each in significant markets and with highly differentiated profiles, the first two of which are expected to be clinical stage next year |
| We believe each of these programs has the potential to transform the treatment of these debilitating conditions |
| Our vision is to develop small molecules that can provide a restorative therapy and work with the patient's natural genome to help cells read the genes in a manner that restores cellular health despite the presence of the mutations |
| Statement |
|---|
| While we knew that the drug was short-lived in plasma |
| Most patients unfortunately quietly suffer from declining visual quality |
| And when cells from unaffected siblings are incubated with the compounds, the frataxin levels remain unaltered |
| We have designed GeneTAC to bind and recognize these long CTG repeat regions in the mutant allele and shut off production of the toxic TCF4 mutant RNA |
| This is exactly what one would wish for an FA, a medicine that restores natural levels of the single gene product that causes all of these problems |
| We learned from the human studies that the duration of adequate levels of exposure of DT-216 was much shorter than expected |
| This causes nuclear foci and -- osteopathy and other cellular dysfunction |
| The prior DT-216 drug product had a rapid elimination from plasma during a period called the alpha phase and its exposure profile, and therefore, drug levels in the plasma were low after only a few hours |
| One is a variety of measures of visual quality, and there are numerous reports in the literature of ways to measure the loss of visual quality in patients with Fuchs |
| The analogy is sometimes that of a foggy and rainy windshield resulting in loss of low contrast, visual acuity glare and contrast sensitivity |
| On the right is a photoshop image composed by a patient to communicate her loss of visual quality in late stage Fuchs |
| Furthermore, investments into new platform companies often suffer from frequent rounds of dilution due to the necessary high R&D burn rates that often require investors that time their investment decisions with great care |
| This profile has a blunted CMAX and a sustained exposure with low peak to trough level fluctuations |
| As HD is a devastating neurodegenerative disease caused by an exonic repeat expansion in the Huntington gene |
Please consider a small donation if you think this website provides you with relevant information